Sugi Predict

Sugi Predict / Compounds / SCHEMBL4473165

SCHEMBL4473165

SCHEMBL4473165

Nc1ccc(OCc2ccccc2)cc1N

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 10/20 0.63
▸ MAOA P21397 3/20 0.63
▸ GAA P10253 1/20 0.63
▸ MAPT P10636 1/20 0.63
▸ RAB9A P51151 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ L3MBTL1 Q9Y468 1/20 0.63
▸ ALOX5 P09917 1/20 0.61
▸ LMNA P02545 1/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ PTGS1 P23219 1/20 0.55
▸ SLC6A2 P23975 1/20 0.55
▸ CYP2C19 P33261 1/20 0.55
▸ PTGS2 P35354 1/20 0.55
▸ SLC6A3 Q01959 1/20 0.55
▸ HIF1A Q16665 1/20 0.55
▸ HDAC6 Q9UBN7 1/20 0.55
▸ CYP3A4 P08684 1/20 0.53
▸ TOP1 P11387 1/20 0.51
▸ GSTP1 P09211 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30040891 1.00 MAOB (0.63) MAOBMAOAGAAMAPTRAB9A
Hydrochloric Acid SCHEMBL9124176 0.98 MAOB (0.61) MAOBMAOAGAAMAPTRAB9A
SCHEMBL11114770 0.85 MAOB (0.59) MAOBMAOAGAAMAPTRAB9A
SCHEMBL273100 0.85 LMNA (0.61) MAOBMAOAGAAMAPTRAB9A
SCHEMBL4053551 0.85 MAOB (0.59) MAOBMAOAGAAMAPTRAB9A
SCHEMBL11749413 0.84 MAOB (0.46) MAOBMAOAGAAMAPTRAB9A
SCHEMBL1894067 0.84 MAOB (0.58) MAOBMAOAGAAMAPTRAB9A
SCHEMBL7447794 0.84 MAOB (0.58) MAOBMAOAGAAMAPTRAB9A
SCHEMBL1744108 0.84 MAOB (0.58) MAOBMAOAGAAMAPTRAB9A
SCHEMBL519206 0.84 MAOB (0.58) MAOBMAOAGAAMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12365681-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2025-07-22 — — US disclosed
EP-4559908-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF S2CBio Inc. (KR) 2025-05-28 — — EP disclosed
CN-118206529-A Dihydrobenzimidazolone C4医药公司 2024-06-18 — — CN disclosed
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
CN-111315735-B Dihydrobenzimidazolone C4医药公司 2024-03-08 — — CN disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 — — US disclosed
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS THE ROCKEFELLER UNIVERSITY 2023-01-26 — — US disclosed
US-20040048868-A1 Benzimidazoles AVENTISUB LLC 2004-03-11 — — US disclosed
US-20040038987-A1 Novel cyclic diamine compounds and medicine containing the same KOWA COMPANY, LTD. (JP) 2004-02-26 — — US disclosed
WO-2003035065-A1 BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS AVENTIS PHARMACEUTICALS INC (US) 2003-05-01 — — WO disclosed
EP-0643701-B1 BENZIMIDAZOLE-DERIVED COMPOUNDS, METHOD FOR PREPARING SAME, AND THERAPEUTICAL AND COSMETIC USES THEREOF CT INTERNAT DE RECH S BR DERMA (FR) 2001-12-05 — — EP disclosed
US-5446059-A Treating or preventing inflammatory or immunoallergic conditions CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1995-08-29 — — US disclosed
EP-0643701-A1 BENZIMIDAZOLE-DERIVED COMPOUNDS, METHOD FOR PREPARING SAME, AND THERAPEUTICAL AND COSMETIC USES THEREOF CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA, ( CIRD GALDERMA) (FR) 1995-03-22 — — EP disclosed
WO-1992021663-A1 BENZIMIDAZOLE-DERIVED COMPOUNDS, METHOD FOR PREPARING SAME, AND THERAPEUTICAL AND COSMETIC USES THEREOF CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1992-12-10 — — WO disclosed
US-4080461-A PESTICIDES, FUNGICIDES SYNTEX (U.S.A.) INC. (US) 1978-03-21 — — US disclosed
US-4072696-A 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity SYNTEX (U.S.A.) INC. (US) 1978-02-07 — — US disclosed
US-4002640-A ANTIFUNGAL AGENTS SYNTEX (U.S.A.) INC. (US) 1977-01-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B MAOB 2815/4885MAOA 2749/4885GAA 125/4885
US-20040048868-A1 Benzimidazoles CDK9, BMX, CDKN1A MAOB 993/4885MAOA 1112/4885GAA 352/4885
US-20230027198-A1 INHIBITORS OF ENL/AF9 YEATS MLLT3, YEATS2, MLLT1 MAOB 2008/4885MAOA 1214/4885GAA 3726/4885
US-12365681-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MAOB 2473/4885MAOA 3584/4885GAA 1982/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 MAOB 2473/4885MAOA 3584/4885GAA 1982/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 MAOB 2473/4885MAOA 3584/4885GAA 1982/4885
US-20040038987-A1 Novel cyclic diamine compounds and medicine containing the same LCAT, ACAT2, ACAT1 MAOB 493/4885MAOA 570/4885GAA 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.